Voraxaze FDA Approval History
FDA Approved: Yes (First approved January 17, 2012)
Brand name: Voraxaze
Generic name: glucarpidase
Dosage form: Injection
Company: BTG International Inc.
Treatment for: Methotrexate Overdosage
Voraxaze (glucarpidase) is a carboxypeptidase enzyme indicated for the treatment of toxic plasma methotrexate levels in patients with delayed methotrexate clearance due to impaired renal function.
Development timeline for Voraxaze
| Date | Article |
|---|---|
| Jan 17, 2012 | Approval FDA Approves Voraxaze to Treat Patients with Toxic Methotrexate Levels |
| Nov 20, 2008 | Protherics PLC Voraxaze Rolling BLA Submission Initiated with the US FDA |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
